{"pmid":32294763,"title":"[Responsibilities of Weaning Centers during the COVID-19 Pandemic Outbreak - Recommendations for the Assignment of ICU Capacities in COVID-19 Patients as shown by the Berlin-Brandenburg POST-SAVE-Model].","text":["[Responsibilities of Weaning Centers during the COVID-19 Pandemic Outbreak - Recommendations for the Assignment of ICU Capacities in COVID-19 Patients as shown by the Berlin-Brandenburg POST-SAVE-Model].","The enormous increase in patients with severe respiratory distress due to the COVID-19 pandemic outbreak requires a systematic approach to optimize ventilated patient at risk flow. A standardised algorithm called \"SAVE\" was developed to distribute patients with COVID-19 respiratory distress syndrome requiring invasive ventilation. This program is established by now in Berlin. An instrumental bottleneck of this approach is the vacant slot assignment in the intensive care unit to guarantee constant patient flow. The transfer of the patients after acute care treatment is needed urgently to facilitate the weaning process. In a next step we developed a triage algorithm to identify patients at SAVE intensive care units with potential to wean and transfer to weaning institutions - we called POST SAVE. This manuscript highlights the algorithms including the use of a standardised digital evaluation tool, the use of trained navigators to facilitate the communication between SAVE intensive care units and weaning institutions and the establishment of a prospective data registry for patient assignment and reevaluation of the weaning potential in the future.","Pneumologie","Wiesner, B","Bachmann, M","Blum, T-G","Forchheim, S","Geiseler, J","Kassin, A","Kretzschmar, E","Weber-Carstens, S","Westhoff, M","Witzenrath, M","Grohe, C","32294763"],"abstract":["The enormous increase in patients with severe respiratory distress due to the COVID-19 pandemic outbreak requires a systematic approach to optimize ventilated patient at risk flow. A standardised algorithm called \"SAVE\" was developed to distribute patients with COVID-19 respiratory distress syndrome requiring invasive ventilation. This program is established by now in Berlin. An instrumental bottleneck of this approach is the vacant slot assignment in the intensive care unit to guarantee constant patient flow. The transfer of the patients after acute care treatment is needed urgently to facilitate the weaning process. In a next step we developed a triage algorithm to identify patients at SAVE intensive care units with potential to wean and transfer to weaning institutions - we called POST SAVE. This manuscript highlights the algorithms including the use of a standardised digital evaluation tool, the use of trained navigators to facilitate the communication between SAVE intensive care units and weaning institutions and the establishment of a prospective data registry for patient assignment and reevaluation of the weaning potential in the future."],"journal":"Pneumologie","authors":["Wiesner, B","Bachmann, M","Blum, T-G","Forchheim, S","Geiseler, J","Kassin, A","Kretzschmar, E","Weber-Carstens, S","Westhoff, M","Witzenrath, M","Grohe, C"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294763","week":"202016|Apr 13 - Apr 19","doi":"10.1055/a-1153-9710","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Berlin"],"countries":["Germany"],"countries_codes":["DEU|Germany"],"_version_":1664266295812554752,"score":8.233237,"similar":[{"pmid":32298146,"title":"Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective.","text":["Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective.","In response to the estimated potential impact of COVID-19 on New York City hospitals, our institution prepared for an influx of critically ill patients. Multiple areas of surge planning progressed simultaneously focused on infection control, clinical operational challenges, intensive care unit surge capacity, staffing, ethics and maintenance of staff wellness. Protocols developed focused on clinical decisions around intubation, the use of high-flow oxygen, infectious disease consultation and cardiac arrest. Mechanisms to increase bed capacity as well as increase efficiency in intensive care units by outsourcing procedures were implemented. Novel uses of technology to minimize staff exposure to COVID-19, as well as to facilitate family engagement and end of life discussions were encouraged. Education and communication remained key in attempting to standardize care, stay apprized on emerging data as well as to review seminal literature on respiratory failure. Challenges were encountered, and overcome through interdisciplinary collaboration and iterative surge planning as intensive care unit admissions rose. Support was provided for both clinical and nonclinical staff affected by the profound impact COVID-19 had on our city. We describe in granular detail, the procedures and processes developed during a one month period while surge planning was ongoing and the need for intensive care unit capacity rose exponentially. The approaches described provide a potential roadmap for centers that must rapidly adapt to the tremendous challenge introduced by this and potential future pandemics. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).","Am J Respir Crit Care Med","Griffin, Kelly M","Karas, Maria G","Ivascu, Natalia S","Lief, Lindsay","32298146"],"abstract":["In response to the estimated potential impact of COVID-19 on New York City hospitals, our institution prepared for an influx of critically ill patients. Multiple areas of surge planning progressed simultaneously focused on infection control, clinical operational challenges, intensive care unit surge capacity, staffing, ethics and maintenance of staff wellness. Protocols developed focused on clinical decisions around intubation, the use of high-flow oxygen, infectious disease consultation and cardiac arrest. Mechanisms to increase bed capacity as well as increase efficiency in intensive care units by outsourcing procedures were implemented. Novel uses of technology to minimize staff exposure to COVID-19, as well as to facilitate family engagement and end of life discussions were encouraged. Education and communication remained key in attempting to standardize care, stay apprized on emerging data as well as to review seminal literature on respiratory failure. Challenges were encountered, and overcome through interdisciplinary collaboration and iterative surge planning as intensive care unit admissions rose. Support was provided for both clinical and nonclinical staff affected by the profound impact COVID-19 had on our city. We describe in granular detail, the procedures and processes developed during a one month period while surge planning was ongoing and the need for intensive care unit capacity rose exponentially. The approaches described provide a potential roadmap for centers that must rapidly adapt to the tremendous challenge introduced by this and potential future pandemics. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)."],"journal":"Am J Respir Crit Care Med","authors":["Griffin, Kelly M","Karas, Maria G","Ivascu, Natalia S","Lief, Lindsay"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298146","week":"202016|Apr 13 - Apr 19","doi":"10.1164/rccm.202004-1037CP","keywords":["SARS virus","intensive care units","pandemics"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664266651297644544,"score":196.85924},{"pmid":32246838,"title":"Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.","text":["Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.","The first person-to-person transmission of the 2019-novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. In Northern Italy in particular, we rapidly experienced a critical care crisis due to a shortage of intensive care beds, as we expected according to data reported in China. Based on our experience of managing this surge, we produced this review to support other healthcare services in preparedness and training of hospitals during the current coronavirus outbreak. We had a dedicated task force that identified a response plan, which included: (1) establishment of dedicated, cohorted intensive care unit(s) (ICU) for COVID-19-positive patients; (2) design of appropriate procedures for pre-triage, diagnosis and isolation of suspected and confirmed cases; and (3) training of all staff to work in the dedicated ICU in personal protective equipment use and patient management. Hospital multidisciplinary and departmental collaboration was needed to work on all principles of surge capacity, including: space definition; supplies provision; staff recruitment; and ad-hoc training. Dedicated protocols were applied where full isolation of spaces, staff and patients was implemented. Opening the unit and the whole hospital emergency process required a multidisciplinary, multilevel involvement of healthcare providers and hospital managers all working towards a common goal: patient care and hospital safety. Hospitals should be prepared to face severe disruptions to their routine and it is very likely that protocols and procedures might require re-discussion and update on a daily basis.","Anaesthesia","Carenzo, L","Costantini, E","Greco, M","Barra, F L","Rendiniello, V","Mainetti, M","Bui, R","Zanella, A","Grasselli, G","Lagioia, M","Protti, A","Cecconi, M","32246838"],"abstract":["The first person-to-person transmission of the 2019-novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. In Northern Italy in particular, we rapidly experienced a critical care crisis due to a shortage of intensive care beds, as we expected according to data reported in China. Based on our experience of managing this surge, we produced this review to support other healthcare services in preparedness and training of hospitals during the current coronavirus outbreak. We had a dedicated task force that identified a response plan, which included: (1) establishment of dedicated, cohorted intensive care unit(s) (ICU) for COVID-19-positive patients; (2) design of appropriate procedures for pre-triage, diagnosis and isolation of suspected and confirmed cases; and (3) training of all staff to work in the dedicated ICU in personal protective equipment use and patient management. Hospital multidisciplinary and departmental collaboration was needed to work on all principles of surge capacity, including: space definition; supplies provision; staff recruitment; and ad-hoc training. Dedicated protocols were applied where full isolation of spaces, staff and patients was implemented. Opening the unit and the whole hospital emergency process required a multidisciplinary, multilevel involvement of healthcare providers and hospital managers all working towards a common goal: patient care and hospital safety. Hospitals should be prepared to face severe disruptions to their routine and it is very likely that protocols and procedures might require re-discussion and update on a daily basis."],"journal":"Anaesthesia","authors":["Carenzo, L","Costantini, E","Greco, M","Barra, F L","Rendiniello, V","Mainetti, M","Bui, R","Zanella, A","Grasselli, G","Lagioia, M","Protti, A","Cecconi, M"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246838","week":"202014|Mar 30 - Apr 05","doi":"10.1111/anae.15072","source":"PubMed","locations":["Italy","China"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663352135836762115,"score":170.79987},{"pmid":32286679,"title":"COVID-19 challenge for modern medicine.","text":["COVID-19 challenge for modern medicine.","Coronaviruses cause disease in animals and people around the world. Human coronaviruses (HCoV) are mainly known to cause infections of the upper and lower respiratory tract but the symptoms may also involve the nervous and digestive systems. Since the beginning of December 2019, there has been an epidemic of SARS-CoV-2, which was originally referred to as 2019-nCoV. The most common symptoms are fever and cough, fatigue, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting or diarrhea (30%). The best prevention is to avoid exposure. In addition, contact persons should be subjected to mandatory quarantine. COVID-19 patients should be treated in specialist centers. A significant number of patients with pneumonia require passive oxygen therapy. Non-invasive ventilation and high-flow nasal oxygen therapy can be applied in mild and moderate non-hypercapnia cases. A lung-saving ventilation strategy must be implemented in acute respiratory distress syndrome and mechanically ventilated patients. Extracorporeal membrane oxygenation is a highly specialized method, available only in selected centers and not applicable to a significant number of cases. Specific pharmacological treatment for COVID-19 is not currently available. Modern medicine is gearing up to fight the new coronavirus pandemic. The key is a holistic approach to the patient including, primarily, the use of personal protective equipment to reduce the risk of further virus transmission, as well as patient management, which consists in both quarantine and, in the absence of specific pharmacological therapy, symptomatic treatment.","Cardiol J","Dzieciatkowski, Tomasz","Szarpak, Lukasz","Filipiak, Krzysztof J","Jaguszewski, Milosz","Ladny, Jerzy R","Smereka, Jacek","32286679"],"abstract":["Coronaviruses cause disease in animals and people around the world. Human coronaviruses (HCoV) are mainly known to cause infections of the upper and lower respiratory tract but the symptoms may also involve the nervous and digestive systems. Since the beginning of December 2019, there has been an epidemic of SARS-CoV-2, which was originally referred to as 2019-nCoV. The most common symptoms are fever and cough, fatigue, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, nausea, vomiting or diarrhea (30%). The best prevention is to avoid exposure. In addition, contact persons should be subjected to mandatory quarantine. COVID-19 patients should be treated in specialist centers. A significant number of patients with pneumonia require passive oxygen therapy. Non-invasive ventilation and high-flow nasal oxygen therapy can be applied in mild and moderate non-hypercapnia cases. A lung-saving ventilation strategy must be implemented in acute respiratory distress syndrome and mechanically ventilated patients. Extracorporeal membrane oxygenation is a highly specialized method, available only in selected centers and not applicable to a significant number of cases. Specific pharmacological treatment for COVID-19 is not currently available. Modern medicine is gearing up to fight the new coronavirus pandemic. The key is a holistic approach to the patient including, primarily, the use of personal protective equipment to reduce the risk of further virus transmission, as well as patient management, which consists in both quarantine and, in the absence of specific pharmacological therapy, symptomatic treatment."],"journal":"Cardiol J","authors":["Dzieciatkowski, Tomasz","Szarpak, Lukasz","Filipiak, Krzysztof J","Jaguszewski, Milosz","Ladny, Jerzy R","Smereka, Jacek"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286679","week":"202016|Apr 13 - Apr 19","doi":"10.5603/CJ.a2020.0055","keywords":["COVID-19","SARS-CoV-2","coronavirus","epidemiology","healthcare","medical stuff","pandemic","symptoms","treatment"],"source":"PubMed","topics":["Diagnosis","Prevention","Treatment"],"weight":1,"locations":["myalgia","arthralgia","headache","diarrhea"],"_version_":1664071627122409473,"score":169.14491},{"pmid":32278097,"title":"The role and response of palliative care and hospice services in epidemics and pandemics: a rapid review to inform practice during the COVID-19 pandemic.","text":["The role and response of palliative care and hospice services in epidemics and pandemics: a rapid review to inform practice during the COVID-19 pandemic.","Cases of COVID-19 are escalating rapidly across the globe, with the mortality risk being especially high among those with existing illness and multimorbidity. This study aimed to synthesise evidence for the role and response of palliative care and hospice teams to viral epi/pandemics, to inform the COVID-19 pandemic response. We conducted a rapid systematic review according to PRISMA guidelines in five databases. Of 3094 papers identified, ten were included in this narrative synthesis. Included studies were from West Africa, Taiwan, Hong Kong, Singapore, the United States and Italy. All had an observational design. Findings were synthesised using a previously proposed framework according to 'systems' (policies, training and protocols, communication and coordination, data), 'staff' (deployment, skill mix, resilience), 'space' (community provision, use of technology) and 'stuff' (medicines and equipment, personal protective equipment). We conclude that hospice and palliative services have an essential role in the response to COVID-19 by: 1) responding rapidly and flexibly; 2) ensuring protocols for symptom management are available, and training non-specialists in their use; 3) being involved in triage; 4) considering shifting resources into the community; 5) considering redeploying volunteers to provide psychosocial and bereavement care; 6) facilitating camaraderie among staff and adopt measures to deal with stress; 7) using technology to communicate with patients and carers; 8) adopting standardised data collection systems to inform operational changes and improve care.","J Pain Symptom Manage","Etkind, Simon N","Bone, Anna E","Lovell, Natasha","Cripps, Rachel L","Harding, Richard","Higginson, Irene J","Sleeman, Katherine E","32278097"],"abstract":["Cases of COVID-19 are escalating rapidly across the globe, with the mortality risk being especially high among those with existing illness and multimorbidity. This study aimed to synthesise evidence for the role and response of palliative care and hospice teams to viral epi/pandemics, to inform the COVID-19 pandemic response. We conducted a rapid systematic review according to PRISMA guidelines in five databases. Of 3094 papers identified, ten were included in this narrative synthesis. Included studies were from West Africa, Taiwan, Hong Kong, Singapore, the United States and Italy. All had an observational design. Findings were synthesised using a previously proposed framework according to 'systems' (policies, training and protocols, communication and coordination, data), 'staff' (deployment, skill mix, resilience), 'space' (community provision, use of technology) and 'stuff' (medicines and equipment, personal protective equipment). We conclude that hospice and palliative services have an essential role in the response to COVID-19 by: 1) responding rapidly and flexibly; 2) ensuring protocols for symptom management are available, and training non-specialists in their use; 3) being involved in triage; 4) considering shifting resources into the community; 5) considering redeploying volunteers to provide psychosocial and bereavement care; 6) facilitating camaraderie among staff and adopt measures to deal with stress; 7) using technology to communicate with patients and carers; 8) adopting standardised data collection systems to inform operational changes and improve care."],"journal":"J Pain Symptom Manage","authors":["Etkind, Simon N","Bone, Anna E","Lovell, Natasha","Cripps, Rachel L","Harding, Richard","Higginson, Irene J","Sleeman, Katherine E"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32278097","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jpainsymman.2020.03.029","keywords":["COVID-19","coronavirus","end of life","hospice","palliative care","pandemic"],"source":"PubMed","locations":["West Africa","China","China","Singapore","United States","Italy"],"countries":["Singapore","United States","China","Italy"],"countries_codes":["SGP|Singapore","USA|United States","CHN|China","ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663798882996322304,"score":167.79288},{"pmid":32292906,"pmcid":"PMC7147194","title":"The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review.","text":["The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review.","Acute respiratory distress is one of the major causes of mortality associated with COVID-19 disease. Many patients will require intensive care with ventilatory support. Despite progress and best efforts, the mortality rates projected remain high. Historical data outlook points towards 80% expected fatality for patients progressing to advanced pulmonary disease, even when hospitalized in the intensive care unit. This is particularly true among the patient population over 65. Novel life-saving strategies are desperately needed to mitigate the high mortality that will be associated with the late stage SARS-CoV-2 viral infection associated with the fatal respiratory distress. We hypothesize that the morbidity, severity of the disease, and underlying physiological events leading to mortality are closely linked to the TRPV1 expressing neuronal system (afferent/efferent neurons) in the lungs. TRPV1 expressing cells are responsible for pain transmission, inflammation and immunomodulation throughout the entire pulmonary system and are modulating the processes associated with localized cytokine release (storm) and overall rapid disease progression. We suggest that therapeutic approaches targeting TRPV1 containing nerve fibers in the lungs will modulate the inflammatory and immune signal activity, leading to reduced mortality and better overall outcomes. We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.","Med Drug Discov","Nahama, Alexis","Ramachandran, Roshni","Cisternas, Alvaro Francisco","Ji, Henry","32292906"],"abstract":["Acute respiratory distress is one of the major causes of mortality associated with COVID-19 disease. Many patients will require intensive care with ventilatory support. Despite progress and best efforts, the mortality rates projected remain high. Historical data outlook points towards 80% expected fatality for patients progressing to advanced pulmonary disease, even when hospitalized in the intensive care unit. This is particularly true among the patient population over 65. Novel life-saving strategies are desperately needed to mitigate the high mortality that will be associated with the late stage SARS-CoV-2 viral infection associated with the fatal respiratory distress. We hypothesize that the morbidity, severity of the disease, and underlying physiological events leading to mortality are closely linked to the TRPV1 expressing neuronal system (afferent/efferent neurons) in the lungs. TRPV1 expressing cells are responsible for pain transmission, inflammation and immunomodulation throughout the entire pulmonary system and are modulating the processes associated with localized cytokine release (storm) and overall rapid disease progression. We suggest that therapeutic approaches targeting TRPV1 containing nerve fibers in the lungs will modulate the inflammatory and immune signal activity, leading to reduced mortality and better overall outcomes. We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease."],"journal":"Med Drug Discov","authors":["Nahama, Alexis","Ramachandran, Roshni","Cisternas, Alvaro Francisco","Ji, Henry"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292906","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100033","keywords":["ARDS","Acute Respiratory Distress Syndrome","COVID-19, SARS-CoV-2","Coronavirus","Cytokine Storm","Inflammation","Innervation","Lungs","RTX","Resiniferatoxin","TRPV1"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664266295831429120,"score":163.88443}]}